Vardenafil hydrochloride tablets are labeled in the United States for erectile dysfunction. The film-coated tablet label describes taking the drug as needed, generally around 60 minutes before sexual activity, with sexual stimulation required for an erection. For most patients the label identifies 10 mg as a starting dose; response and tolerability may lead the prescriber to consider other labeled doses. None of these label statements selects an individual reader’s regimen.
Dose selection is more than picking among 2.5 mg, 5 mg, 10 mg, and 20 mg tablets. Age, liver impairment, the presence of interacting medicines, alpha-blocker treatment, cardiovascular status and side effects can materially change a prescribing decision. Separate labeling applies to the 10 mg orally disintegrating presentation, which cannot simply be substituted for a film-coated 10 mg tablet. Of particular importance, certain CYP3A4 inhibitors impose limits of 2.5 mg over 72 hours rather than the ordinary once-daily frequency rule.
This page explains the U.S. dosing framework and why clinician oversight matters. The strengths catalog documents available tablet numbers, while the administration guide covers practical prescribed use. People comparing formulations should also read the ODT-specific page.
U.S. labeling for film-coated vardenafil identifies a usual starting point of 10 mg for most adults, with the clinician able to decrease to 5 mg or increase to a maximum recommended 20 mg based on response and side effects. These are regulatory descriptions of a prescribed medication, not self-titration instructions. The maximum recommended dosing frequency is once per day.
Timing is also part of the regimen: the product is ordinarily used in anticipation of sexual activity, not on an automatic daily schedule. The medication does not generate an erection independently of stimulation. The practical meaning of “around 60 minutes” is discussed on the onset page, which should not be read as a promise of an exact response time.
| Label element | Film-coated tablet context | Interpretation |
|---|---|---|
| Usual starting point | 10 mg for most patients | Prescriber considers other relevant factors |
| Adjusted labeled range | 5 mg to 20 mg for common adjustments | Not a self-directed titration plan |
| Listed 2.5 mg presentation | Product-specific label and interaction context | Do not infer universal availability or instructions |
| Timing | Approximately 60 minutes before activity | Individual response is variable |
| Maximum frequency | Once per day | Do not add an extra dose after an unsatisfactory response |
The maximum frequency in a drug label limits how often medication may be administered. It does not say an erection lasts that entire period, nor does it authorize repeating a dose whenever effects feel incomplete. Duration, subjective response, half-life, and safe repeat-dosing rules are different concepts.
Vardenafil has an elimination half-life of approximately four to five hours, but that pharmacokinetic measurement cannot be used to set a personal redosing time. The duration guide separates those concepts in more detail.
Current U.S. film-coated tablet labeling recommends considering a 5 mg starting dose in adults aged 65 or older. In moderate hepatic impairment (Child-Pugh B), the recommended starting dose is 5 mg and the maximum is 10 mg. Labels advise against use in severe hepatic impairment (Child-Pugh C) and in patients undergoing renal dialysis. These restrictions differ from the usual maximum of 20 mg for many patients.
Do not adjust tablet strength or divide tablets on the basis of an online table. The prescriber must review the specific product, organ function, interacting medicines and cardiovascular risk. The separate tablet-strength pages describe the presentations, not individualized treatment rules.
Vardenafil is metabolized largely by CYP3A4. Certain current U.S. film-coated labels specify no more than 2.5 mg in any 72-hour period with ritonavir or cobicistat. They also specify no more than 2.5 mg in 24 hours with indinavir, saquinavir, atazanavir, clarithromycin, or ketoconazole/itraconazole at 400 mg daily; and no more than 5 mg in 24 hours with ketoconazole/itraconazole at 200 mg daily or erythromycin. These are interactions severe enough that ordinary 'once daily' wording is not sufficient.
These figures summarize label-defined limits for specific film-coated products, not an algorithm for patients to choose a dose. A prescribed combination might require a different ED treatment, and the ODT product has separate cautions. Always give the clinician and pharmacist the exact co-medication, its dose and the dispensed vardenafil dosage form. The interaction guide covers the mechanisms and class distinctions.
The ordinary 10 mg starting point and once-per-day maximum do not summarize all approved prescribing situations. The U.S. film-coated label distinguishes older age, impaired liver function, dialysis and specific CYP3A4 inhibitors. The table records clinically important prescribing limits so that readers can recognize why a prescriber may reject an otherwise familiar tablet strength; it is not a self-dosing worksheet.
Different vardenafil applicants can have label revisions or formulation-specific instructions. These limits must be checked against the actual supplied label, especially when a medicine is started or stopped by another clinician.
| Circumstance | Film-coated label example | Critical distinction |
|---|---|---|
| Age 65 or older | Consider 5 mg starting dose | Not an automatic recommendation for every older adult |
| Moderate hepatic impairment (Child-Pugh B) | 5 mg starting dose; maximum 10 mg | Ordinary 20 mg maximum does not apply |
| Severe hepatic impairment or renal dialysis | Do not use according to specified labels | No self-selected reduction resolves this issue |
| Ritonavir or cobicistat | No more than 2.5 mg in 72 hours | Special interval replaces ordinary once-daily ceiling |
| Selected other strong CYP3A4 inhibitors | Limits as low as 2.5 mg in 24 hours | Exact interacting agent and regimen matter |
| Other CYP3A4 inhibitors including erythromycin | Some label limits are 5 mg in 24 hours | Must verify the specific agent and label |
The orally disintegrating 10 mg presentation has separate instructions: place on the tongue, allow it to dissolve, use without liquid, and follow its prescribed as-needed timing. It produces greater systemic exposure than the identically numbered film-coated 10 mg presentation. The two forms are therefore expressly not interchangeable.
Patients needing a lower or higher dose than the ODT formulation provides may require a separately prescribed film-coated product. ODT rules for certain interacting medicines and organ impairments also differ from those for film-coated tablets. A comparison of milligram figures alone obscures these differences.
Vardenafil must not be combined with organic nitrates or nitric-oxide donors, or with the guanylate-cyclase stimulator riociguat. Those combinations can cause serious hypotension. Additional attention is needed for alpha-blockers, antihypertensive drugs, and a personal or medication history involving QT prolongation.
The label advises patients with congenital QT prolongation or certain class IA/III antiarrhythmic therapies to avoid vardenafil. This is not a risk that can be eliminated by selecting the smallest tablet. See nitrate contraindications and interaction screening.
Unsatisfactory response can have multiple explanations, including incorrect use, insufficient stimulation, an untreated contributing condition, medication effects, or realistic variability. A perceived lack of effect on one occasion does not automatically justify taking more medication.
A prescriber may revisit the diagnosis, review medical history and expectations, or discuss a different treatment plan rather than escalating a dose. For interpreting the expected start of response see the onset explanation.
Ask which formulation is prescribed, what the pharmacy should dispense, whether current medicines create serious interactions, which adverse symptoms require urgent care, and when to report treatment problems. A written medication list should include prescription, over-the-counter, and recreational substances.
Check the final pharmacy label before use. A valid U.S. prescription and licensed dispensing remain necessary; obtaining the right instructions is a medical task, not a reason to buy from a no-prescription vendor. The prescription guide covers that process.
The labeled starting framework assumes a clinician has first determined that treating ED with this medication is appropriate. Cardiovascular fitness for sexual activity, a relevant history of fainting, medications used for pulmonary hypertension, and other important health information can affect whether vardenafil should be considered at all.
A dose listed in official prescribing information therefore should be read as a clinician-facing framework. It cannot be transformed into personalized instructions simply by matching an age category or a single health characteristic.
During follow-up, a clinician can ask whether an adequately instructed trial produced a useful response and whether headache, flushing, nasal symptoms or more serious effects occurred. This review helps distinguish tolerability concerns from errors in administration or an underlying condition that needs separate care.
Any dose modification should be tied to a documented treatment plan and accurate pharmacy instructions. A new label should be reviewed carefully, especially if the patient previously used a different ED medicine or formulation.
U.S. labeling describes 10 mg for most adults, while the prescriber considers age, medicines, organ function and response.
The film-coated label describes 20 mg as the maximum recommended dose; this is not an instruction for someone to increase treatment.
The ordinary film-coated label limits dosing to once daily, but some CYP3A4 interactions demand longer intervals. For example, specified labels limit vardenafil to 2.5 mg over 72 hours with ritonavir or cobicistat. Follow the prescribed product instructions rather than the general rule alone.
Its U.S. film-coated ED labeling describes as-needed use; this is different from certain tadalafil daily regimens.
No. The ODT produces different systemic exposure and has separate administration instructions.
Yes. Clarithromycin, erythromycin and certain azole antifungals can trigger specific lower-dose or longer-interval limits in the U.S. film-coated tablet label. A prescriber or pharmacist must verify the exact product and interacting medicine.
No. Organic nitrate use is contraindicated with vardenafil regardless of the chosen strength.
Do not independently repeat or increase medication. Discuss response and permitted frequency with the prescribing clinician.